1. Home
  2. HRMY vs DCO Comparison

HRMY vs DCO Comparison

Compare HRMY & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$32.44

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Ducommun Incorporated

DCO

Ducommun Incorporated

HOLD

Current Price

$136.91

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
DCO
Founded
2017
1849
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
HRMY
DCO
Price
$32.44
$136.91
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$44.11
$153.60
AVG Volume (30 Days)
799.5K
191.9K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
$824,730,000.00
Revenue This Year
$19.75
$7.40
Revenue Next Year
$12.88
$8.59
P/E Ratio
$11.72
N/A
Revenue Growth
21.51
4.85
52 Week Low
$25.52
$59.42
52 Week High
$40.87
$145.90

Technical Indicators

Market Signals
Indicator
HRMY
DCO
Relative Strength Index (RSI) 66.25 49.96
Support Level $32.13 $135.26
Resistance Level $33.21 $143.08
Average True Range (ATR) 1.32 5.60
MACD 0.19 -0.65
Stochastic Oscillator 58.88 10.94

Price Performance

Historical Comparison
HRMY
DCO

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: